Sorafenib, an oral multikinase inhibitor, is the first approved targeted agent for advanced HCC; it targets vascular endothelial growth factor receptor (VEGFR)-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-α and β, and serine-threonine kinases (Raf-1 and B-Raf) involved in tumor cell proliferation and tumor angiogenesis [6, 7]. The gene discussed is BRAF; the disease is neoplasm.